MBBP Client Valeritas Receives FDA 510(k) Clearance for Insulin Delivery Device 03/17/2011Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: FDA, insulin delivery, Valeritas
MBBP client Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, has gained clearance from the U.S. Food and Drug Administration on the company’s V-Go Disposable Insulin Delivery Device for use with Novo Nordisk’s NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. At the end of 2010, Valeritas received FDA clearance for the V-Go’s use with Eli Lilly’s Humalog®.
Valeritas’ V-Go is the first simple, fully disposable device for the delivery of basal-bolus insulin therapy for adults with diabetes, and it is the first use of the Valeritas h-Patch™ technology.
For more information, visit www.valeritas.com.